GBC Business Summary

General Biologicals Corporation (GBC) is a vertically integrated biotechnology firm specializing in the development, manufacture, and global distribution of in-vitro diagnostic (IVD) solutions and precision medicine technologies. The company generates revenue primarily through the sale of diagnostic kits and reagents across three core segments: Immunoassays (ELISA/RIA), Molecular Diagnostics (Real-Time PCR), and Liquid Biopsy (CellBio™ CTC detection). GBC also operates a Contract Development and Manufacturing Organization (CDMO) for IVD raw materials and maintains a pharmaceutical division focused on P113 antimicrobial peptide therapeutics for oral and skin care. In the competitive landscape, GBC contends with global giants such as Abbott Laboratories and Roche Holding AG in the hepatitis and infectious disease markets, while facing local competition from Taiwanese peers like TaiDoc Technology and LabTurbo. GBC distinguishes itself through its legacy as a pioneer in Taiwan’s National Hepatitis Prevention Program and its recent expansion into high-sensitivity automated cancer screening systems. Founded in 1984 by Dr. Zong Mei Lin, GBC is currently led by Chairman and General Manager Frank Lin, who oversees the company’s strategic shift toward digital healthcare and AI-powered diagnostics. The leadership team includes Director TC Lin, who brings extensive executive experience from roles at Danner Lab and Pacgen Life Science, and Board Member Pi-Hua Chen, representing the interests of CHLITINA Holding Limited. The company’s governance is supported by a board that includes independent directors with backgrounds in clinical research and biotech consulting, such as Cheryl Lin. Notable institutional backing and significant shareholding are provided by Dehui International Co., Ltd. and Mega International Investment Trust, reflecting a stable investor base as the company expands its footprint into South American and Southeast Asian markets.